Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The efficacy of immune checkpoint inhibitors (ICIs), including toripalimab and pembrolizumab, has not been confirmed in the treatment of cancer of unknown primary (CUP), which has a very poor prognosis. Combined with anti-angiogenic therapies, ICIs are hypothesized to be effective in prolonging overall survival. The study aims to give evidence on the treatment effects of sunitinib combined with ICIs, find pathological biomarkers associated with changes in volumetric F FDG PET/CT parameters, and investigate inner associations among these markers associated with response on PET/CT.
Methods: The study recruited patients receiving combined treatment (ICIs + sunitinib), compared the effects of combined treatment with those of separate treatment and age-matched negative controls, and analyzed propensity score-matched (PSM) pairs. Markers associated with survival were identified, and their inner associations were tested using structural equation modeling.
Results: A total of 292 patients were enrolled in the final analysis, with 53 patients receiving combined treatment. Survival analysis demonstrated significantly prolonged survival in either combined or separate treatment, with the combined arm showing better response when PSM-paired using pre-treatment whole-body PET/CT parameters. The angiogenic markers KDR and VEGF mediate the PD-1 blockade impact on volumetric value changes in positive and negative manners.
Conclusion: The anti-angiogenic agent sunitinib may potentiate PD-1 blockade by diminishing angiogenesis or its downstream effects. The combined separate treatment increased the survival of CUP patients, and the responses could be evaluated using volumetric PET/CT parameters.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777842 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1191611 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of bone oligometastases in breast cancer using models based on deep learning radiomics of PET/CT imaging.
Front Oncol
August 2025
Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Objective: To develop a deep learning radiomics(DLR)model integrating PET/CT radiomics, deep learning features, and clinical parameters for early prediction of bone oligometastases (≤5 lesions) in breast cancer.
Methods: We retrospectively analyzed 207 breast cancer patients with 312 bone lesions, comprising 107 benign and 205 malignant lesions, including 89 lesions with confirmed bone metastases. Radiomic features were extracted from computed tomography (CT), positron emission tomography (PET), and fused PET/CT images using PyRadiomics embedded in the uAI Research Portal.
[F]FDG-PET provides insights into the liver-brain axis and confirms SUV as a surrogate for MR in a mouse model of liver fibrosis.
Nucl Med Biol
September 2025
Department of Nuclear Medicine, Hannover Medical School, Germany. Electronic address:
Purpose: The liver-brain axis regulates metabolic homeostasis, with glucose metabolism playing a key role. Liver dysfunction, such as fibrosis, may impact brain metabolism and consequently, brain function. Positron emission tomography (PET) imaging provides a non-invasive approach to study glucose metabolism in both organs.
View Article and Find Full Text PDFArtificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [F]FDG PET/CT study.
Eur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFEffect of bone marrow disease on hematologic toxicity and response to [Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging.
Eur J Nucl Med Mol Imaging
September 2025
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
Purpose: Despite the effectiveness of [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [Lu]Lu-PSMA-617.
Methods: This retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [Lu]Lu-PSMA-617.
YOLO-ED: An efficient lung cancer detection model based on improved YOLOv8.
PLoS One
September 2025
School of Computer Science and Engineering, Macau University of Science and Technology, Macau, China.
In recent years, You Only Look Once (YOLO) models have gradually been applied to medical image object detection tasks due to their good scalability and excellent generalization performance, bringing new perspectives and approaches to this field. However, existing models overlook the impact of numerous consecutive convolutions and the sampling blur caused by bilinear interpolation, resulting in excessive computational costs and insufficient precision in object detection. To address these problems, we propose a YOLOv8-based model using Efficient modulation and dynamic upsampling (YOLO-ED) to detect lung cancer in CT images.
View Article and Find Full Text PDF